These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26109876)

  • 1. Clinical utility of naloxegol in the treatment of opioid-induced constipation.
    Bruner HC; Atayee RS; Edmonds KP; Buckholz GT
    J Pain Res; 2015; 8():289-94. PubMed ID: 26109876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem.
    Yoon SC; Bruner HC
    Patient Prefer Adherence; 2017; 11():1265-1271. PubMed ID: 28769555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Peripherally Acting μ-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review.
    Rekatsina M; Paladini A; Drewes AM; Ayob F; Viswanath O; Urits I; Corli O; Pergolizzi J; Varrassi G
    Cureus; 2021 Jul; 13(7):e16201. PubMed ID: 34367804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
    van Malderen K; Halawi H; Camilleri M
    Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
    Pergolizzi JV; Christo PJ; LeQuang JA; Magnusson P
    Drug Des Devel Ther; 2020; 14():1009-1025. PubMed ID: 32210534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.
    Streicher JM; Bilsky EJ
    J Pharm Pract; 2018 Dec; 31(6):658-669. PubMed ID: 28946783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of naloxegol in the management of opioid-induced bowel dysfunction.
    Leppert W; Woron J
    Therap Adv Gastroenterol; 2016 Sep; 9(5):736-46. PubMed ID: 27582887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation.
    Anantharamu T; Sharma S; Gupta AK; Dahiya N; Singh Brashier DB; Sharma AK
    J Pharmacol Pharmacother; 2015; 6(3):188-92. PubMed ID: 26312011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy.
    Pergolizzi JV; Raffa RB; Pappagallo M; Fleischer C; Pergolizzi J; Zampogna G; Duval E; Hishmeh J; LeQuang JA; Taylor R
    Patient Prefer Adherence; 2017; 11():107-119. PubMed ID: 28176913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction.
    Poulsen JL; Brock C; Olesen AE; Nilsson M; Drewes AM
    Clin Exp Gastroenterol; 2014; 7():345-58. PubMed ID: 25278772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxegol , a new drug for the treatment of opioid-induced constipation.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2015 Feb; 16(3):399-406. PubMed ID: 25496063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.
    De Giorgio R; Zucco FM; Chiarioni G; Mercadante S; Corazziari ES; Caraceni A; Odetti P; Giusti R; Marinangeli F; Pinto C
    Adv Ther; 2021 Jul; 38(7):3589-3621. PubMed ID: 34086265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of oral naloxegol vs subcutaneous methylnaltrexone in treatment of opioid-induced constipation in the hospital setting.
    Nero R; Allen B; Hailu K; Noor R; Theiss K
    Am J Health Syst Pharm; 2023 May; 80(Suppl 2):S70-S76. PubMed ID: 36440903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid-induced constipation in chronic noncancer pain.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):11-7. PubMed ID: 26702846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain.
    Viscusi ER
    Clin J Pain; 2019 Feb; 35(2):174-188. PubMed ID: 30289777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral Opioid Receptor Antagonists for Opioid-Induced Constipation: A Primer on Pharmacokinetic Variabilities with a Focus on Drug Interactions.
    Gudin J; Fudin J
    J Pain Res; 2020; 13():447-456. PubMed ID: 32158255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
    Holder RM; Rhee D
    Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
    White WB; Kowey P; Diva U; Sostek M; Tummala R
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
    Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
    Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.